Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.bbc.co.uk/sport/football/51532949
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of octopustravel.com
Are you over 18 and want to see adult content?
A complete backup of pressreleasefinder.com
Are you over 18 and want to see adult content?
A complete backup of engagesciences.com
Are you over 18 and want to see adult content?
A complete backup of phuketactive.com
Are you over 18 and want to see adult content?
A complete backup of 1websdirectory.com
Are you over 18 and want to see adult content?
Text
OVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process. NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorCOMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular TERMS - TISSUE GENESIS Terms and Conditions. Orgenesis owns and operates this web site (“Site”). The Terms and Conditions (“Terms and Conditions”) set forth in this agreement (“Agreement”) govern any use of the publicly accessible portions of the Site.ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
CLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study.ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served as TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANYOVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process. NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorCOMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular TERMS - TISSUE GENESIS Terms and Conditions. Orgenesis owns and operates this web site (“Site”). The Terms and Conditions (“Terms and Conditions”) set forth in this agreement (“Agreement”) govern any use of the publicly accessible portions of the Site.ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
CLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study.ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served as TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.CLINICAL USE
The Icellator ® has already been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and The Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions.PUBLICATIONS
The study evaluated a point-of-care technology, the Tissue Genesis ‘‘TGI 1000’’ Cell Isolation System, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. Inconclusion, the
IN DEVELOPMENT
Tissue Genesis is committed to the highest levels of safety and quality with all its products. To minimize contamination and prevent animal-derived pathogens during the cell isolation process, TG is developing a clinically superior grade of Adipase ®, the enzyme used to digest adipose tissue and free the SVF from the surroundingcellular matrix.
ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
CONTACT - TISSUE GENESIS Corporate Headquarters. 2113 State Street. New Albany, IN 47150. 1-502-265-4830. info@koligo.net ICELLATOR® X PHOTO GALLERY 2021 Tissue Genesis . Scroll to topCARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2CLINICAL INQUIRIES
Clinical Inquiries. To speak directly with one of our national account managers, please fill out the below form and someone will respond within 24 hours. Name (required) Email (required) Message.SALES & SUPPORT
1. Doi, K., Tanaka, S., Iida, H., Eto, H., Kato, H., Aoi, N., Kuno, S., Hirohi, T. and Yoshimura, K. (2013), Stromal vascular fraction isolated from lipo-aspirates HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANYOVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original Icellator TERMS - TISSUE GENESIS Terms and Conditions. Orgenesis owns and operates this web site (“Site”). The Terms and Conditions (“Terms and Conditions”) set forth in this agreement (“Agreement”) govern any use of the publicly accessible portions of the Site.ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).CARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served as TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANYOVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original Icellator TERMS - TISSUE GENESIS Terms and Conditions. Orgenesis owns and operates this web site (“Site”). The Terms and Conditions (“Terms and Conditions”) set forth in this agreement (“Agreement”) govern any use of the publicly accessible portions of the Site.ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).CARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served as TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascularPUBLICATIONS
The study evaluated a point-of-care technology, the Tissue Genesis ‘‘TGI 1000’’ Cell Isolation System, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. Inconclusion, the
CLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study. CONTACT - TISSUE GENESIS Corporate Headquarters. 2113 State Street. New Albany, IN 47150. 1-502-265-4830. info@koligo.netAPPLICATIONS
Applications – OUS. The Icellator ® has been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and the Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions.CARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2 ICELLATOR® X PHOTO GALLERY 2021 Tissue Genesis . Scroll to topPAUL KOSNIK, PH.D.
Dr. Paul Kosnik is responsible for business development and managing interactions with the clinical trial sites and medical experts. He also serves as the Tissue Genesis Principal Investigator for the Critical Limb Ischemia trial funded by the federal government. Previously, Dr. Kosnik served as the Vice President of Engineering atTissue
BEN CHLEBINA, MBA
As General Manager of Tissue Genesis, Ben Chlebina manages the operational, strategic planning, financial and marketing efforts of the Tissue Genesis management to optimize growth and maximize value. Passionate about regenerative medicine and translational research, Mr. Chlebina joined HHIG with a career focused on biomedical research anddrug
HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANYOVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served asCARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2 TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANYOVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served asCARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2 TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.PUBLICATIONS
The study evaluated a point-of-care technology, the Tissue Genesis ‘‘TGI 1000’’ Cell Isolation System, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. Inconclusion, the
CONTACT - TISSUE GENESIS Corporate Headquarters. 2113 State Street. New Albany, IN 47150. 1-502-265-4830. info@koligo.netCLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study.CARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2APPLICATIONS
Applications – OUS. The Icellator ® has been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and the Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions.DISTRIBUTORS
North America & Caribbean. Tissue Genesis, LLC; Japan & China: Human Life CORD Japan, Inc., (HLC) Europe/Middle East. Tissue Genesis, LLC ICELLATOR® X PHOTO GALLERY 2021 Tissue Genesis . Scroll to topCLINICAL INQUIRIES
Clinical Inquiries. To speak directly with one of our national account managers, please fill out the below form and someone will respond within 24 hours. Name (required) Email (required) Message.CHRISTINA GIESE
Christina Giese serves as Chief Human Resources Officer for Tissue Genesis, Houston Healthspan Innovation Group and Capital Technologies, Inc., (The Bosarge Family Office). She has over 18 years of experience in all areas of Human Resources including HR process and policy development, benefits design and management, compliance, employee HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANYOVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served asCARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2 TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANYOVERVIEW
The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served asCARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2 TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for PRODUCTS - TISSUE GENESIS The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.PUBLICATIONS
The study evaluated a point-of-care technology, the Tissue Genesis ‘‘TGI 1000’’ Cell Isolation System, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. Inconclusion, the
CONTACT - TISSUE GENESIS Corporate Headquarters. 2113 State Street. New Albany, IN 47150. 1-502-265-4830. info@koligo.netCLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study.CARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2APPLICATIONS
Applications – OUS. The Icellator ® has been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and the Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions.DISTRIBUTORS
North America & Caribbean. Tissue Genesis, LLC; Japan & China: Human Life CORD Japan, Inc., (HLC) Europe/Middle East. Tissue Genesis, LLC ICELLATOR® X PHOTO GALLERY 2021 Tissue Genesis . Scroll to topCLINICAL INQUIRIES
Clinical Inquiries. To speak directly with one of our national account managers, please fill out the below form and someone will respond within 24 hours. Name (required) Email (required) Message.CHRISTINA GIESE
Christina Giese serves as Chief Human Resources Officer for Tissue Genesis, Houston Healthspan Innovation Group and Capital Technologies, Inc., (The Bosarge Family Office). She has over 18 years of experience in all areas of Human Resources including HR process and policy development, benefits design and management, compliance, employee HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANY OVERVIEWTISSUE GENESIS INCTISSUE GENESIS TOWER HONOLULU The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorPUBLICATIONS
The study evaluated a point-of-care technology, the Tissue Genesis ‘‘TGI 1000’’ Cell Isolation System, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. Inconclusion, the
IN DEVELOPMENT
Tissue Genesis is committed to the highest levels of safety and quality with all its products. To minimize contamination and prevent animal-derived pathogens during the cell isolation process, TG is developing a clinically superior grade of Adipase ®, the enzyme used to digest adipose tissue and free the SVF from the surroundingcellular matrix.
ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
CLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study.ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served as HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANY OVERVIEWTISSUE GENESIS INCTISSUE GENESIS TOWER HONOLULU The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorPUBLICATIONS
The study evaluated a point-of-care technology, the Tissue Genesis ‘‘TGI 1000’’ Cell Isolation System, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. Inconclusion, the
IN DEVELOPMENT
Tissue Genesis is committed to the highest levels of safety and quality with all its products. To minimize contamination and prevent animal-derived pathogens during the cell isolation process, TG is developing a clinically superior grade of Adipase ®, the enzyme used to digest adipose tissue and free the SVF from the surroundingcellular matrix.
ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
CLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study.ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served asCLINICAL USE
The Icellator ® has already been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and The Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions. MEDIA - TISSUE GENESIS Videos. Watch instructional and promotional videos about Tissue Genesis and its products. CONTACT - TISSUE GENESIS Corporate Headquarters. 2113 State Street. New Albany, IN 47150. 1-502-265-4830. info@koligo.net ICELLATOR® X PHOTO GALLERY 2021 Tissue Genesis . Scroll to topDISTRIBUTORS
North America & Caribbean. Tissue Genesis, LLC; Japan & China: Human Life CORD Japan, Inc., (HLC) Europe/Middle East. Tissue Genesis, LLCAPPLICATIONS
Applications – OUS. The Icellator ® has been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and the Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions.CARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2REQUEST INFO
Request Info. To request additional information about Tissue Genesis and its advanced cell processing products, please fill out the below form. Name (required) Email (required) Message. TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center forCHRISTINA GIESE
Christina Giese serves as Chief Human Resources Officer for Tissue Genesis, Houston Healthspan Innovation Group and Capital Technologies, Inc., (The Bosarge Family Office). She has over 18 years of experience in all areas of Human Resources including HR process and policy development, benefits design and management, compliance, employee HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANY OVERVIEWTISSUE GENESIS INCTISSUE GENESIS TOWER HONOLULU The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process. NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorCOMPANY OVERVIEW
About Tissue Genesis. What if a powerful source of regenerative medicine is within your own body? At Tissue Genesis, this idea doesn’t just inspire us, it is a catalyst motivating us to develop and refine industry-leading innovation with real-world cell therapyapplications.
PUBLICATIONS
Summary: The expression of adhesion molecules with known functions in regulating the homing or mobilization of stem cells differs between these 2 cell preparations.ADSCs express CD48d (4-integrin, which forms a heterodimer with CD29 to create very late activation antigen-4, VLA-4, the main cognate ligand for vascular cell adhesion molecule-1 –CD106 ligand), whereas cells derived fromCOMPANY HISTORY
Tissue Genesis (TG) combines over twenty years of tissue engineering expertise with the development of advanced cell biology research hardware for NASA, NIH and DoD on the Space Shuttle and ISS.ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).CLINICAL TRIALS
Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using TGI Device. Status: Completed Conditions: Facial Injuries,Tissue Injury
ICELLATOR® X
THE ICELLATOR ® X BENEFITS. Consistently isolates high stromal vascular fraction (SVF) cell yields. Includes multiple types of adult stem cells. Provides cell product in about an hour.ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for morethan 15 years.
HOME - TISSUE GENESISABOUTPRODUCTSCLINICAL USEMEDIACONTACTCOMPANY OVERVIEWTISSUE GENESIS INCTISSUE GENESIS TOWER HONOLULU The new Icellator ® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator ® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications. ABOUT TISSUE GENESIS Company Overview. Tissue Genesis (TG) offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process.COMPANY OVERVIEW
Tissue Genesis, founded in 2001, is rooted in bio-engineering with a combined twenty plus years of cell culture modelling, including the development of advanced cell biology flight hardware for NASA, NIH and DOD on the Space Shuttle and ISS. Concurrently, Tissue Genesis has focused on the more earthly medical needs of peripheral vascular NEWS - TISSUE GENESIS The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine. Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. The Icellator® X expands on the capabilities of the original IcellatorPUBLICATIONS
The study evaluated a point-of-care technology, the Tissue Genesis ‘‘TGI 1000’’ Cell Isolation System, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. Inconclusion, the
COMPANY HISTORY
Tissue Genesis Company History. Tissue Genesis (TG) combines over twenty years of tissue engineering expertise with the development of advanced cell biology research hardware for NASA, NIH and DoD on the Space Shuttle and ISS. This highly successful space research program was directed at rapid “aging-like” symptoms presenting inastronauts
ICELLATOR®
THE ICELLATOR ® BENEFITS. Isolates consistent yield of stromal vascular fraction (SVF). Includes multiple types of adult stem cells. Provides yields of pure SVF in 65 minutes or less, allowing for intravenous infusion (Bahamas NSCEC Protocol: HEA/GB-1/OK-004).ICELLATOR® X
The new Icellator ® X is a state-of-the-art, enzyme-derived stem cell isolation system. Effective with minimal amount of adipose tissue. Totally enclosed and automated process. Temperature control optimizes SVF yield per mL of adipose tissue. Cell suspension safe for IV delivery. Features a sterile, single-use, disposable cartridgetreatment kit.
CLINICAL TRIALS
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction. Status: Active, not recruiting. Conditions: Erectile Dysfunction. View Study.ANTON C. KRUCKY
Board of Managers. Mr. Anton C. Krucky co-founded Tissue Genesis, Inc. in 2001, serving as its Chief Executive Officer and President for more than 15 years. Now a member of the Board of Managers, Mr. Krucky has decades of global management experience that includes product development, marketing and sales. While working for IBM, he served asIN DEVELOPMENT
Tissue Genesis is committed to the highest levels of safety and quality with all its products. To minimize contamination and prevent animal-derived pathogens during the cell isolation process, TG is developing a clinically superior grade of Adipase ®, the enzyme used to digest adipose tissue and free the SVF from the surroundingcellular matrix.
CLINICAL USE
The Icellator ® has already been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and The Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions. MEDIA - TISSUE GENESIS Videos. Watch instructional and promotional videos about Tissue Genesis and its products. CONTACT - TISSUE GENESIS Corporate Headquarters. 2113 State Street. New Albany, IN 47150. 1-502-265-4830. info@koligo.netDISTRIBUTORS
North America & Caribbean. Tissue Genesis, LLC; Japan & China: Human Life CORD Japan, Inc., (HLC) Europe/Middle East. Tissue Genesis, LLCCARTRIDGE KIT
1. Joel A. Aronowitz, Ryan A. Lockhart, Cloe S. Hakakian (2015), Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue: 4:713 DOI 10.1186/s40064-015-1509-2APPLICATIONS
Applications – OUS. The Icellator ® has been approved for commercial use in Korea as a Class III medical device by the Korean FDA (KMFDS) and has been used in more than 1,200 commercial applications. The Ukraine and the Bahamas have also given regulatory approval for Tissue Genesis’ patented, clinical grade cell therapy processing solutions. ICELLATOR® X PHOTO GALLERY 2021 Tissue Genesis . Scroll to topREQUEST INFO
Request Info. To request additional information about Tissue Genesis and its advanced cell processing products, please fill out the below form. Name (required) Email (required) Message. TISSUE GENESIS' ICELLATOR® X DELIVERS RESULTS IN FIRST New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Automated point-of-care device extracts adult stem cells from adiposetissue.
WATCH OUR VIDEO
Icellator® X provides consistent high SVF cell yields in 65 minutes.LEARN MORE
SALES AND CUSTOMER SUPPORT HOTLINE 844-991-3999* Home
* About
* Company Overview
* Company History
* Executive Leadership* Publications
* Products
* ICELLATOR® X
* ICELLATOR®
* Cartridge Kit with Adipase®* In Development
* Clinical Use
* Clinical Trials – US * Applications – OUS* Distributors
* Media
* News
* Product Literature* Photo Gallery
* Videos
* Contact
* Clinical Inquiries* Request Info
* Tech Support
* English
* 简体中文
* 繁體中文
* Français
* Deutsch
* 日本語
* 한국어
* Русский
* Español
* Search
* MENU
The New Icellator® Xis here for 2019!
WATCH OUR VIDEO
The most advanced enzyme-derived cell processing solution.LEARN MORE
ICELLATOR® X
MORE FAT AND CELL YIELD. IT’S HERE! The new Icellator® X moves Tissue Genesis forward as the leader in the production of stromal vascular fraction (SVF) from a patient’s own adipose (fat)-derived stem cells. The 2019 Icellator® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.Learn More
CARTRIDGE KIT
ADIPASE® ENZYME BLEND The Cartridge Kit is compatible with both our new Icellator® X and original Icellator®. Our proprietary kit offers a sterile, single-use disposable cartridge using adipose tissue for high-efficiency enzyme-derived, SVF isolation. The entire system minimizes cell variability, and maximizes yield and cell viability.Learn More
ICELLATOR®
CELL ISOLATION SYSTEM The original Icellator® system set the standard, providing SVF cell yields in 65 minutes. Currently approved for use in South Korea, Bahamas, Ukraine and available in Japan. In the USA, clinical FDA-approved IDE studies using the Icellator® are underway for a variety of indications. Information and Support THE POTENTIAL OF ADIPOSE, ENZYME-DERIVED ADULT STEM CELLS IN REGENERATIVE MEDICINE IS LIMITLESS. 2019 Tissue Genesis Scroll to topDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0